AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.
Key PointsThe company is expanding both approved and pipeline therapies...
Nasdaq News: Markets
More News
AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA/VENCLYXTO (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA/VENCLYXTO (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA/VENCLYXTO (venetoclax) in First-Line...
PR Newswire
Will Skyrizi & Rinvoq Continue to Drive AbbVie's Topline Through 2026?
ABBV's Skyrizi and Rinvoq post strong Q1 growth, lift 2026 sales outlooks and sustain momentum through new indications.
Zacks
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?
Ironwood sees Linzess momentum as strong demand, a pediatric expansion and pricing changes are expected to boost revenues and profit in 2026.
Zacks
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings?
ANIP trades at 9.75x forward earnings after raising 2026 guidance, but investors must weigh Cortrophin-led growth against competition and customer concentration.
Zacks
ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push
ANIP expands Cortrophin into acute gout flares with a 90-person sales force as investors watch adoption, spending and 2026 milestones.
Zacks
ANIP Pharmaceuticals' Cortrophin Gel Drives 2026 Growth
ANIP bets on Cortrophin Gel to power 2026 growth as rare disease sales become the majority of revenues. What must keep working?
Zacks
Morgan Stanley, Shake Shack, Cboe Global Markets And A Health Care Stock On CNBC's 'Final Trades'
Joshua Brown is still bullish on Shake Shack, while Malcolm Ethridge recommends Morgan Stanley and Jim Lebenthal picks AbbVie Inc. as their final trades.read more...
Benzinga
What's Driving Amneal's 2026 Growth Outlook?
AMRX's 2026 outlook is driven by higher profit expectations, a steady launch cadence, and growth from complex generics, injectables, and specialty brands.
Zacks
Middle East Erupts Again: Buy these Healthcare ETFs Before the Next Strike
Healthcare ETFs are gaining attention as Middle East tensions and market volatility boost demand for defensive sectors.